Q4FY22 Quarterly Result Announced for Syngene International Ltd.
Pharmaceuticals firm Syngene International declares Q4FY22 result: Syngene reports full year revenue from operations up 19% to Rs. 2604 Cr The Company reported revenue from operations up 15% to Rs. 758 Cr for the fourth quarter and up 19% to Rs. 2604 Cr for the full year ending 31 March 2022. Profit After Tax for the quarter, before accounting for exceptional items, was up 7% year-on-year to Rs. 148 Cr. Profit After Tax for the full year was up 10% to Rs. 421 Cr. Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, “I am pleased with the strong finish we had to the year and that we delivered results at the high end of our upgraded guidance range. Reflecting on the pandemic period, we created more than 1000 new jobs in the last two years and gained more than 100 new clients in the last year. We also extended and expanded our long-term partnership with Amgen Inc. and continued to invest in new capacity and technology to underpin future growth. Looking ahead, we see growing demand for research, development and manufacturing services around the world and we are well-positioned to take advantage of these new opportunities.” Result PDF27-04-2022